To this end, we explored the fractions of various immune cells and cancer neoantigens within cytolytic subgroups in CRC, and predicted which of them would respond better to a hypothetical treatment with CTLA-4 and PD-1 blockers, either alone or in combination. This evidence concerns the gene CTLA4 and cancer.